ipharmacenter Consulting services

NICE’s decision to accept higher cost‑per‑QALY ratios is more than a technical parameter change; it reflects a domestic adjustment to a broader bargain the UK has struck with the United States to pay more for branded medicines in return for zero tariffs on British pharmaceutical exports. That combination of trade and health‑policy concessions is likely to shape how other tax‑funded health systems define value, manage finite drug budgets and approach negotiations with global m

The UK government announced on December 1, 2025, an increase in the National Institute for Health and Care Excellence (NICE) thresholds used to evaluate new medicines' cost-effectiveness for the National Health Service (NHS). NICE increased cost effectiveness threshold from £20,000-£30,000/QALY to £25,000-£35,000/QALY This adjustment raises the standard range from £20,000 - £30,000 per quality-adjusted life year (QALY) gained to £25,000 - £35,000 per QALY, aiming to foster in

Hundreds of adults in England living with a rare and aggressive form of blood cancer could soon access a potentially life-saving therapy, following new guidance from the National Institute for Health and Care Excellence (NICE).   NICE has recommended obecabtagene autoleucel, also known as obe-cel or Aucatzyl, for routine NHS use in patients aged 26 and over with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL). The decision marks an important step forward for

Patients in England suffering from severe beta-thalassaemia will soon have access to a groundbreaking one-time gene therapy,...

New Systemic Treatment Option Recommended for Patients Aged 12 and Over The National Institute for Health and Care Excellence (NICE) has...

Innovative Oral Therapy Approved for Over 40,000 Patients The National Institute for Health and Care Excellence (NICE) in the UK has...

CSL Behring's Hemgenix has been recommended for managed access as a treatment option for adults with moderately severe or severe...

Keytruda (pembrolizumab) combined with trastuzumab, fluoropyrimidine, and platinum-based chemotherapy is not recommended for initial...

Ivosidenib Plus Azacitidine Endorsed by NICE for Treating Acute Myeloid Leukaemia in Adults Ineligible for Standard Induction...

Aquipta, recommended by NICE, presents a new option for preventing migraines in adults with at least 4 migraine days monthly after at...

NICE announced that artificial intelligence (AI)-derived solutions are available for implementation within the NHS as further evidence is...

January 10, 2024 NICE recommended Alexion's Kanuma for LAL deficiency Sebelipase alfa, marketed as Kanuma by Alexion, holds an indication...

Camzyos (mavacamten) has been recommended as a viable option for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in...

Yescarta has been recommended for adults with diffuse large B-cell lymphoma (DLBCL) after one treatment and is currently indicated as the...

December 15, 2022 SOBI's Doptelet was recommended for treating refractory primary chronic immune thrombocytopenia. NICE recommended using...